

NANO ONE MATERIALS CORP.

CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2017

(Expressed in Canadian dollars)





NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2017

The accompanying unaudited condensed interim financial statements of Nano One Materials Corp. (the "Company") for the period ended March 31, 2017 have been prepared by, and are the responsibility of, the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with the standards established by the Canadian Institute of Chartered Accountants for a review of the interim financial statements by an entity's auditor.

NANO ONE MATERIALS CORP. CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION (unaudited)

(Expressed in Canadian Dollars)

	March 31, 2017	December 31, 2016
ASSETS	\$	\$
ASSETS		
Current assets		
Cash and cash equivalents	1,794,664	2,439,244
Receivables	472,512	483,131
Prepaids	123,781	78,070
Total current assets	2,390,957	3,000,445
Equipment, net	298,452	301,305
Pilot plant, net (Note 5)	1,438,364	844,774
Intangible assets	1,314	1,314
•	<u> </u>	
	1,738,130	1,147,393
Total assets	4,129,087	4,147,838
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued liabilities	321,721	449,735
Accounts payable to related parties	-	7,650
Deferred government grant (Note 6)	79,630	200,341
Total current liabilities	401,351	657,726
Chaughaldous' aguitu		
Shareholders' equity	12 101 200	11 046 700
Share capital (Note 9) Equity reserves (Note 9)	13,181,298 1,166,144	11,846,703 1,710,320
Deficit	(10,619,706)	(10,066,911)
Delioit	(10,013,100)	(10,000,311)
Total shareholders' equity	3,727,736	3,490,112
Total liabilities and shareholders' equity	4,129,087	4,147,838

Nature and continuance of operations (Note 1)

Events after the reporting date (Note 14)

Approved and authorized by the Board on May 24, 2017

NANO ONE MATERIALS CORP. CONDENSED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (unaudited) (Expressed in Canadian Dollars)

THREE MONTHS ENDED MARCH 31

	2017	2016
	\$	\$
OPERATING EXPENSES		
Consulting	55,011	40,300
Depreciation	3,168	2,324
Filing and regulatory fees	16,185	18,611
Office and general	18,766	8,433
Professional fees	68,036 `	31,872
Rent	14,599	6,500
Research and development	265,490	118,372
Salary and benefits	108,341	79,118
Shareholder communication and investor relations	46,185	179,952
Share-based payments (Note 9)	64,786	150,649
Travel	16,774	-
Operating expenses	(677,341)	(636,131)
Interest income	2,790	1,808
Loss and comprehensive loss for the period	(674,551)	(634,323)
Basic and diluted loss per common share	(0.01)	(0.01)
Weighted average number of common shares outstanding	58,675,763	45,475,183

NANO ONE MATERIALS CORP. CONDENSED INTERIM STATEMENTS OF CASH FLOW (unaudited)

(Expressed in Canadian Dollars)

THREE MONTHS ENDED MARCH 31

	2017	2016
	\$	\$
CASH FLOWS FROM OPERATING ACTIVITIES		
Loss for the period Items not affecting cash:	(674,551)	(634,323)
Depreciation	19,510	10,895
Share-based payments	64,786	150,649
Changes in non-cash working capital items:		
Decrease in receivables	10,619	54,795
Increase in prepaids	(45,711)	(238,732)
Decrease in accounts payable and accrued liabilities	(128,014)	(99,600)
Decrease in accounts payable to related parties	(7,650)	-
Decrease in deferred government grant	(120,711)	-
Cash used in operating activities	(881,722)	(756,316)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of equipment	(13,795)	-
Purchase of pilot plant	(596,452)	-
Cash provided by investing activities	(610,247)	
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issuance of share capital	847,389	844,350
Share issuance costs		(3,215)
Cash provided by financing activities	847,389	841,135
Change in cash during the period	(644,580)	84,819
Cash, beginning of period	2,439,244	1,316,506
Cash, end of period	1,794,664	1,401,325
Cash	137,170	771,782
Cash equivalents	1,657,494	629,543
Cash and cash equivalents, end of period	1,794,664	1,401,325

Supplemental disclosures with respect to cash flows (Note 11)

NANO ONE MATERIALS CORP. CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (unaudited)

(Expressed in Canadian Dollars)

	SHARE	CAPITAL	Equity Reserves	<u>s</u>	
	Number of				
	Shares		Share-based		
	outstanding	Amount	payments	Deficit	Total equity
Balance at December 31, 2015	44,793,599	\$ 7,093,942	\$ 1,880,545	\$ (7,524,353)	\$ 1,450,134
Share-based payments	-	-	150,649	-	150,649
Exercise of stock options	125,000	51,379	(20,129)	-	31,250
Exercise of warrant	1,467,000	467,979	(27,879)	-	440,100
Private placement	1,243,333	373,000	-	-	373,000
Share issuance costs	-	(3,215)	-	-	(3,215)
Loss for the period	-	- 1	-	(634,323)	(634,323)
Balance at March 31, 2016	47,628,932	7,983,085	1,983,186	(8,158,676)	1,807,595
Share-based payments	-	-	456,937	-	456,937
Exercise of stock options	325,000	133,246	(53,996)	-	79,250
Exercise of warrants	8,394,052	3,168,311	(642,533)	-	2,525,778
Exercise of finder warrants	165,300	115,924	(33,274)	-	82,650
Private placement	1,406,250	450,000	· -	-	450,000
Share issuance costs	-	(3,863)	-	-	(3,863)
Loss for the period	-	-	=	(1,908,235)	(1,908,235)
Balance at December 31, 2016	57,919,534	11,846,703	1,710,320	(10,066,911)	3,490,112
Share-based payments	-	-	64,786	-	64,786
Exercise of warrants	1,099,682	910,607	(360,766)	-	549,841
Exercise of finders warrants	595,096	417,336	(119,788)	-	297,548
Expiry of warrants	· -	6,652	(128,408)	121,756	-
Loss for the period	-	-	- ′	(674,551)	(674,551)
Balance at March 31, 2017	59,614,312	\$ 13,181,298	\$ 1,166,144	\$(10,619,706)	\$ 3,727,736

(Expressed in Canadian Dollars)

FOR THE PERIOD ENDED MARCH 31, 2017

Page 1

1. NATURE AND CONTINUANCE OF OPERATIONS

Nano One Materials Corp. (the "Company") was incorporated under the laws of the Province of Alberta on November 5, 1987 and continued under the laws of the Province of British Columbia on September 8, 2004. The Company trades on the TSX Venture Exchange. To date, the Company has not earned significate revenues.

The Company's head office address is Unit 101B, 8575 Government Street, Burnaby, BC V3N 4V1, Canada. The registered and records office address is Suite 2900 – 550 Burrard Street, Vancouver, BC V6C 0A3. The financial statements of the Company are presented in Canadian dollars unless otherwise indicated.

At the date of the condensed interim financial statements, the Company has not yet realized profitable operations and it has relied on non-operational sources of financing to fund operations. The ability of the Company to achieve its objectives, meet its ongoing obligations and recover its investments in pending patents and assets will depend on management's ability to successfully execute its business plan, achieve profitable operations and obtain additional financing, if or when required. There is no assurance that these initiatives will be successful.

These condensed interim financial statements have been prepared assuming the Company will continue on a going-concern basis. The Company has incurred losses since inception and the ability of the Company to continue as a going-concern depends upon its ability to develop profitable operations and to continue to raise adequate financing. Management is actively targeting sources of additional financing through alliances with financial, or other business and financial transactions which would assure continuation of the Company's operations. In order for the Company to meet its liabilities as they come due and to continue its operations, the Company is solely dependent upon its ability to generate such financing. These circumstances comprise a material uncertainty which may cast significant doubt as to the ability of the Company to continue as a going concern.

There can be no assurance that the Company will be able to continue to raise funds, in which case the Company may be unable to meet its obligations. Should the Company be unable to realize its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded in these financial statements.

The condensed interim financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

These condensed interim financial statements, including comparatives, have been prepared in accordance with International Accounts Standards ("IAS") 34, "Interim Financial Reporting" using accounting policies consistent with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC").

These condensed interim financial statements should be read in conjunction with the audited financial statements of the Company as at and for the year ended December 31, 2016.

The condensed interim financial statements have been prepared using accounting policies consistent with those used in the Company's 2016 audited financial statements.

(Expressed in Canadian Dollars)

FOR THE PERIOD ENDED MARCH 31, 2017

Page 2

The condensed interim financial statements have been prepared on a historical cost basis, except for certain financial instruments classified at fair value through profit or loss which are stated at their fair value. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting.

The preparation of financial statements in compliance with IFRS requires management to make certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The areas involving a higher degree of judgment of complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in Note 4.

3. RECENT ACCOUNTING STANDARDS

The following standards have been issued but are not yet effective:

IFRS 9 Financial Instruments is part of the IASB's wider project to replace IAS 39 Financial Instruments: Recognition and Measurement. IFRS 9 retains but simplifies the mixed measurement model and establishes two primary measurement categories for financial assets: amortized cost and fair value. The basis of classification depends on the entity's business model and the contractual cash flow characteristics of the financial asset. The standard is effective for annual periods beginning on or after January 1, 2018.

IFRS 15 Revenue from Contracts with Customers is a new standard which establishes a new five-step model for revenue arising from contracts with customers. Revenue is recognized as the amount that reflects the consideration to which any entity expects to be entitled to in exchange for transferring goods or services to a customer. IFRS 15 is effective for periods beginning on or after January 1, 2018.

IFRS 16 is a new standard that sets out the principles for recognition, measurement, presentation, and disclosure of leases including guidance for both parties to a contract, the lessee and the lessor. The new standard eliminates the classification of leases as either operating or finance leases as is required by IAS 17 and instead introduces a single lessee accounting model. The standard is effective for annual periods beginning on or after January 1, 2019.

The Company has not yet completed the process of assessing the impact these standards will have on its financial statements. There are no other standards or IFRIC interpretations that are not yet effective that would be expected to have a material impact on the Company.

4. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS

The Company makes estimates and assumptions about the future that affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions.

The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both.

Information about critical judgments in applying accounting policies and sources of estimation uncertainty that have the most significant risk of causing material adjustment to the carrying amounts

(Expressed in Canadian Dollars)

FOR THE PERIOD ENDED MARCH 31, 2017

Page 3

of assets and liabilities recognized in the condensed interim financial statements within the next financial year are the same as those that applied to the Company's 2016 annual financial statements.

5. PILOT PLANT

	Forklift	Pilot	
	and equip	plant equip	Total
Cost	\$	\$	\$
Balance, December 31, 2015	-	-	-
Additions	27,480	821,874	849,354
Disposals _	-	-	-
Balance, December 31, 2016	27,480	821,874	849,354
Additions	-	596,452	596,452
Disposals			
Balance, March 31, 2017	27,480	1,418,326	1,445,806
Accumulated depreciation			
Balance, December 31, 2015	-	-	-
Depreciation for the year	4,580	-	4,580
Disposals	-	-	-
Balance, December 31, 2016	4,580	-	4,580
Depreciation for the period	2,862	-	2,862
Disposals _	-	-	-
Balance, March 31, 2017	7,442	-	7,442
Carrying amounts			
As at December 31, 2016	22,900	821,874	844,774
As at March 31, 2017	20,038	1,418,326	1,438,364

\$2,862 (2016 - \$Nil) of depreciation has been recorded in research and development expenses.

6. GOVERNMENT ASSISTANCE

Effective June 1, 2016, the Company was granted by the NRC-IRAP a non-repayable contribution of up to \$222,857 (claimed - \$112,867). NRC-IRAP requires that the proceeds from the grant be applied towards the development of High Voltage Cobalt Free Cathode Materials. Under the terms of the agreement, NRC-IRAP has agreed to reimburse the Company for 80% of salaries paid to Company employees and 50% of supported contractor fees involved in this pilot facility. A total of \$35,767 (2016 - \$Nil) was claimed by the Company during the period ending March 31, 2017.

Effective June 1, 2016, the Company executed a contribution agreement with Sustainable Development Technology Canada for up to \$2.08 million technology commercialization grant and received the initial instalment of \$488,994 for the first phase of a lithium battery materials pilot plant project. Funds are dispersed at the beginning of each phase and are subject to the Company meeting milestones and having matching funds in place. A total of \$79,630 has been allocated as deferred government grant as at March 31, 2017.

Effective June 1, 2016, the Company was awarded up to \$1.9 million (claimed - \$364,201) from Innovation, Science and Economic Development Canada (ISED). Automotive Supplier's Innovation Program (ASIP) requires that the proceeds from the grant be applied to the preparation, design, construction, optimization and operation of a pilot plant. A total of \$Nil (2016 - \$Nil) was claimed by the Company during the period ending March 31, 2017.

(Expressed in Canadian Dollars)

FOR THE PERIOD ENDED MARCH 31, 2017

Page 4

Total government assistance recognized for the period ended March 31, 2017 was \$156,478 (2016 - \$25,103). The amount is offset against research and development expense on the statement of loss and comprehensive loss.

7. COMMITMENTS

During the year ended December 31, 2016, the Company entered into an operating lease for its corporate head office. During the period ended March 31, 2017 the Company incurred \$10,565 (2016 - \$Nil) in rental expense. The annual lease commitments under the lease are as follows:

Within one year	\$ 40,958
Within two to three years	61,972
Total	\$ 102,930

During the year ended December 31, 2016, the Company entered into an operating lease for its lab and pilot plant facility. During the period ended March 31, 2017 the Company incurred \$15,703 (2016 - \$Nil) in rental expense. The annual lease commitments under the lease are as follows:

Within one year	\$ 60,880
Within two to three years	92,115
Total	\$ 152,995

On April 15, 2011, the Company entered into an Assignment and Royalty Agreement (the "Agreement") with Lithium Ion Power LLC ("LIP") and Teresita F. Kullberg ("Kullberg") that will survive until the last patent issued under any of the technologies expires. In accordance with the Agreement, Kullberg and LIP assigned to the Company all of its rights, title and interest in and to the technologies and all such rights in and to any and all improvements. The Company must pay a royalty of 3% on net revenues from all consideration collected or received from the marketing, manufacturing, sale or distribution of or licensing the right to do any of the same of the goods manufactured with the use of all or some of the technologies. As at December 31, 2016, the Company had not yet generated any revenue, therefore, no royalties have been paid or accrued.

(Expressed in Canadian Dollars)

FOR THE PERIOD ENDED MARCH 31, 2017

Page 5

8. RELATED PARTY TRANSACTIONS

Key management personnel are the persons responsible for the planning, directing and controlling the activities of the Company and includes both executive and non-executive directors, and entities controlled by such persons. The Company considers all Directors and Officers of the Company to be key management personnel.

The following transactions were carried out with related parties:

(a) Purchases of services

	March 31, 2017 \$	March 31, 2016 \$
An entity where an executive director is an officer, for consulting fees	15,000	15,000
An entity we an executive director is an officer, for miscellaneous operating expenses	1,491	-
An entity where an executive director is an officer, for employee benefits	11,418	5,767
	27,909	20,767

(b) Key management compensation

Key management includes directors (executive and non-executive), the, Chief Executive Officer President and Chief Financial Officer. The compensation paid or payable to key management for employee services is shown below:

	March 31, 2017 \$	March 31, 2016 \$
Salary and benefits to an officer	18,161	19,491
Salary and benefits to an officer and executive director	18,897	20,283
Salary and benefits to and officer and executive director	31,733	34,083
Share-based payments to officers and directors	-	66,246
	68,791	140,103

(Expressed in Canadian Dollars)

FOR THE PERIOD ENDED MARCH 31, 2017

Page 6

9. SHARE CAPITAL AND EQUITY RESERVES

(a) Common shares

The authorized share capital of the Company consists of unlimited common shares without par value.

As at March 31, 2017, 1,932,574 (December 31, 2016 – 2,898,861) of the Company's issued common shares were held in escrow and restricted from trading. These trading restrictions expire as follows:

September 5, 2017	966,287
March 5, 2018	966,287
	1,932,574

Changes in issued share capital and equity reserves for the period ended March 31, 2017 were as follows:

- 1. 595,096 finder's warrants with an exercise price of \$0.50 were exercised for gross proceeds of \$297,548. Accordingly, \$119,788 was transferred from equity reserves to share capital
- 2. 295,000 warrants with an exercise price of \$0.50 were exercised for gross proceeds of \$147,500
- 3. 1,609,364 warrants exercised into 804,682 common shares at an exercise price of \$0.50 per share were exercised for gross proceeds of 402,341 Accordingly, \$360,766 was transferred from equity reserves to share capital.

Changes in issued share capital and equity reserves for the period ended March 31, 2016 were as follows:

- 1. 125,000 stock options with an exercise price of \$0.25 were exercised for gross proceeds of \$31,250. Accordingly, \$20,129 was transferred from equity reserves to share capital.
- 2. 138,500 warrants with an exercise price of \$0.30 were exercised for gross proceeds of \$41,550. Accordingly, \$27,879 was transferred from equity reserves to share capital.
- 3. 1,328,500 warrants with an exercise price of \$0.30 were exercised for gross proceeds of \$398,550.
- 4. The Company completed a non-brokered private placement of 1,243,333 common shares of the Company at a price of \$0.30 each for gross proceeds of \$373,000.

(b) Stock option plan

The Company has a stock option plan under which it is authorized to grant options to directors, officers, consultants and employees enabling them to acquire up to 5,375,236 common shares. The exercise price of each option shall not be less than the discounted market price of the Company's stock as calculated on the date of grant. The options can be granted for a maximum term of ten years. All options are to be settled by physical delivery of shares.

FOR THE PERIOD ENDED MARCH 31, 2017

Page 7

Stock option transactions and the number of stock options outstanding are summarized as follows:

	Number of	Weighted Average Exercise
	Options	Price
Balance at December 31, 2016	4,450,000	\$ 0.29
Granted	147,500	0.70
Balance at March 31, 2017	4,597,500	0.30
Exercisable as at March 31, 2017	3,830,000	0.28

At March 31, 2017 the following stock options were outstanding:

Number of Options	Exercise Price	Expiry Date
2,825,000	\$0.25	March 5, 2020
100,000	\$0.25	December 1, 2020
225,000	\$0.25	January 19, 2021
1,050,000	\$0.35	February 25, 2021
100,000	\$0.38	April 8, 2021
50,000	\$0.50	September 13, 2021
100,000	\$0.53	May 11, 2021
147,500	\$0.70	March 10, 2022
4,597,500		_

(c) Share-based payments

The total share-based payments calculated under the fair value method for options granted during the period was \$65,119 (2016 – \$405,438). The share-based payments expense for the period was \$64,786 (2016 - \$150,649). Fair value at grant date of the stock option plan was measured based on the Black-Scholes option-pricing model. Expected volatility is estimated by considering historic average share price volatility. The weighted average assumptions used for the Black-Scholes option-pricing model of stock options granted and vested during the period are as follows:

	March 10, 2017
	·
Risk-free interest rate	1.26%
Expected life of options	5 years
Annualized volatility	69.05%
Dividend rate	0.00%

NANO ONE MATERIALS CORP.

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (unaudited)

(Expressed in Canadian Dollars)

FOR THE PERIOD ENDED MARCH 31, 2017

Page 8

(d) Warrants

At March 31, 2017, warrants were outstanding enabling holders to acquire the following number of shares:

	Balance, December				Exercise	Balance, March	
Issued date	31, 2016	Issued	Exercised	Expired	price \$	31, 2017	Expiry date
March 5, 2015	2,152,414	-	1,609,364	543,050	0.25*	-	March 5, 2017
March 5, 2015	345,000	-	295,000	50,000	0.50	-	March 5, 2017
March 5, 2015	614,700	-	595,096	19,604	0.50	-	March 5, 2017
	3,112,114	-	2,499,460	612,654		-	

^{*}one-half of one common share at an exercise price of \$0.50 per share

10. MANAGEMENT OF CAPITAL

The Company's objective when managing capital is to safeguard its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain optimal capital structure to reduce to the cost of capital. The Company's capital is composed of equity in the statement of financial position.

The Company is not subject to externally imposed capital requirements. In managing capital structure, the company manages its capital through regular reports to the Board of Directors, as well as management review of monthly or quarterly financial information. The Company issues new equity financing as needed and available. Additional information relating to capital management is given in the nature and continuance of operations in Note 1.

11. SUPPLEMENTAL CASH FLOW INFORMATION

Significant non-cash transactions for the period ended March 31, 2017 included:

- a) The Company allocated \$119,788 for finder's warrants exercised during the period to share capital from equity reserves.
- b) The Company allocated \$360,766 for warrants exercised during the period to share capital from equity reserves.

Significant non-cash transactions for the period ended March 31, 2016 included:

- a) The Company allocated \$20,129 for stock option exercised during the period to share capital from equity reserves.
- b) The Company allocated \$27,879 for warrant exercised during the period to share capital from equity reserves.

12. FINANCIAL INSTRUMENTS

The Company is exposed to various financial instrument risks and assesses the impact and likelihood of this exposure. These risks include liquidity, credit, currency, interest rate, and price risks. Where material, these risks are reviewed and monitored by the Board of Directors.

(Expressed in Canadian Dollars)

FOR THE PERIOD ENDED MARCH 31, 2017

Page 9

Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its obligations associated with its financial liabilities. The Company has historically relied upon equity financings to satisfy its capital requirements and will continue to depend heavily upon equity capital and possible loans to finance its activities. The Company manages liquidity risk through its capital management as outlined above. Accounts payable and accrued liabilities are due within one year.

Credit Risk

Credit risk is the risk of potential loss to the Company if the counterparty to a financial instrument fails to meet its contractual obligations. The Company's credit risk is primarily attributable to its liquid financial assets including cash and cash equivalents, and receivables. The Company limits exposure to credit risk on liquid financial assets through maintaining its cash with high-credit quality financial institutions.

The majority of the Company's cash and cash equivalents is held with major Canadian based financial institutions. The Company considers credit risk with respect to the receivables to be minimal.

Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in market interest rates. Current cash is generally not exposed to interest rate risk because of their short-term maturity.

Price Risk

The Company is exposed to price risk with respect to equity prices. Equity price risk is defined as the potential adverse impact on the Company's earnings due to movements in individual equity prices. The Company closely monitors the individual equity movements to determine the appropriate course of action to be taken by the Company.

Based on management's knowledge and experience of the financial markets, management does not believe that the Company's current financial instruments will be affected by interest rate risk, currency risk and credit risk.

Fair Value

The Company classifies its fair value measurements in accordance with the three-level fair value hierarchy as follows:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 Inputs that are not based on observable market data.

Cash and cash equivalents are measured at fair value based on level 1 of the fair value hierarchy.

(Expressed in Canadian Dollars)

FOR THE PERIOD ENDED MARCH 31, 2017

Page 10

Financial Assets

The estimated fair value of financial assets is equal to their carrying values due to the short-term nature of these instruments. The Company's financial assets were held in the following currencies

Stated in Canadian Dollars

March 31, 2017

Carrying Value	Canadian Dollar	US Dollar	Total
Cash	133,420	3,750	137,170
Cash equivalents	1,657,494	-	1,657,494
Cash and cash equivalents	1,790,914	3,750	1,794,664
Receivables	472,512	-	472,512

Financial Liabilities

The estimated fair value of financial liabilities is equal to their carrying values due to the short-term nature of these instruments. The Company's financial liabilities were held in the following currencies:

Stated in Canadian Dollars

March 31, 2017

Carrying Value	Canadian Dollar	US Dollar	Total
Accounts payable and accrued liabilities	292,320	29,401	321,721
Deferred government grant	79,630	-	79,630

13. SEGMENTED INFORMATION

The Company operates in one business segment, developer of patent pending technology for the production of nanostructured materials.

14. EVENTS AFTER THE REPORTING DATE

Subsequent to March 31, 2017:

1. The Company granted 25,000 stock options at \$0.73 per share expiring May 4, 2022